Pharmacology Preconference
This preconference is a unique Pharmacology program intended for both general practice or specialty clinicians who care for patients with heart failure including practitioners, clinical nurse specialists, registered nurses and other providers interested in pharmacologic management. This program is designed to enhance the participants’ knowledge of pharmacologic treatment options and recent advances in managing patients with heart failure and comorbidities. Experts from across the United States will share timely pharmacologic information and will utilize examples and case studies to facilitate understanding. This program will provide educational content for those new or who only see a few patients with heart failure, as well as challenge the experienced clinician.
DateJune 28, 2023Credits1.5 Contact Hours (AANP)Objectives
- Describe major changes in the management of patients with heart failure
- Discuss the current challenges in managing heart failure patients.
- Highlight the future of pharmacological heart failure management.
Speaker
Robert Mentz, MD
DateJune 28, 2023Credits1 Contact Hours (AANP)Objectives
- Describe the epidemiology and pathophysiological connection between heart failure and amyloid.
- Highlight the mechanism of action, pharmacokinetics, side effects, contraindications, and monitoring parameters for the new approved medications for amyloid.
- Using evidenced based data, discuss the role medications have in the management of patients with heart failure and amyloid.
Speaker
Amrut Ambardekar, MD
DateJune 28, 2023Credits1 Contact Hours (AANP)Objectives
- Highlight the current evidence regarding genomics management of patients with heart failure.
- Identify strategies to implement into practice that facilitate recognition and alternatives to
- ensure individualized optimal treatment of heart failure.
Speaker
Karen Vuckovic, PhD, APRN, ACNS-BC, FAHAUniversity of Illinois at Chicago- DateJune 28, 2023Credits0.5 Contact Hours (AANP)
Objectives
- Given a patient with heart failure, identify key changes in pharmacologic management based on the new guidelines.
- Given a patient with amyloid, highlight new pharmacologic treatment and considerations.
- Given a minority patient with heart failure, what are the considerations of the new available pharmacologic treatment.
Speakers
Robert Mentz, MDAmrut Ambardekar, MDKaren Vuckovic, PhD, APRN, ACNS-BC, FAHAUniversity of Illinois at ChicagoRobert Page, PharmD, MSPHUniversity of Colorado 
DateJune 28, 2023Credits1 Contact Hours (AANP)Objectives
- Introduce the types of cardiotoxicities associated with cancer therapy including risk factors and mechanisms of toxicity
- Understand the incidence of chemotherapy-associated cardiomyopathy and the use of various diagnostic tools for identification and monitoring
- Review strategies to minimize the risk of and risks associated with chemotherapy-associated cardiomyopathy
Speaker
Arwa Omary, PharmD, BCCP- DateJune 28, 2023Credits1 Contact Hours (AANP)
Objectives
- Discuss the current challenges with transitioning the heart failure patient from the hospital.
- Delineate specific methods to transition the patient with HF to home or a rehabilitation facility.
Speaker
Katherine E. DiPalo, Pharm D 
DateJune 28, 2023Credits0.75 Contact Hours (AANP)Objectives
- Given a patient with heart failure and a large comorbidity burden, identify specific issues in the pharmacological management of this patient.
- Given a minority patient with heart failure and a large comorbidity burden, develop a therapeutic plan for the management of the patient’s heart failure.
Speaker
Sita Swamy, DNP ARNP FNP-BC C- DateJune 28, 2023Credits1 Contact Hours (AANP)
Objectives
- Discuss barriers to medication adherence in heart failure
- Describe strategies when meeting with patients to facilitate medication adherence.
Speaker
Chris Bell, ACNP
